Should I buy CVS Health stock in 2025?
Is CVS Health stock a buy right now?
ScoreAs of early May 2025, CVS Health stock is trading at approximately $69.45, with an average daily trading volume of about 10.64 million shares—reflecting robust interest from institutional and retail investors alike. In recent weeks, CVS Health has delivered standout Q1 results: revenue climbed to $94.6 billion and adjusted EPS surged to $2.25, well surpassing market expectations. These results have prompted management to raise full-year guidance, underpinned by continued strength across all core business segments, especially the Health Care Benefits division. Notable developments include an expanded partnership with Novo Nordisk for GLP-1 medications and a decision to streamline offerings by exiting the individual exchange business, both seen as constructive moves for long-term operational efficiency. The positive year-to-date performance and the strong 'Buy' signal from the majority of technical indicators indicate renewed confidence in CVS Health’s integrated healthcare strategy. In a healthcare sector marked by ongoing transformation and demand for value-based care, CVS Health’s diversified, vertically integrated model provides stability and growth potential. Reflecting consensus from more than 29 national and international banks, the stock’s medium-term price target is set at $90—a level suggesting there could be further upside for attentive investors.
- ✅Consistent double-digit EPS growth and robust operating cash flow in recent quarters.
- ✅Integrated healthcare model combines insurance, pharmacy, and retail—enhancing synergies and patient reach.
- ✅Raised full-year financial guidance following strong Q1 2025 performance.
- ✅Broad diversification: 9,000+ pharmacy locations and 27 million medical members via Aetna.
- ✅Attractive 3.8% dividend yield and below-market volatility (0.57 beta).
- ❌Healthcare cost trends remain elevated, possibly impacting short-term profitability.
- ❌Ongoing competitive and regulatory pressures in Medicare and pharmacy segments.
- ✅Consistent double-digit EPS growth and robust operating cash flow in recent quarters.
- ✅Integrated healthcare model combines insurance, pharmacy, and retail—enhancing synergies and patient reach.
- ✅Raised full-year financial guidance following strong Q1 2025 performance.
- ✅Broad diversification: 9,000+ pharmacy locations and 27 million medical members via Aetna.
- ✅Attractive 3.8% dividend yield and below-market volatility (0.57 beta).
Is CVS Health stock a buy right now?
ScoreAs of early May 2025, CVS Health stock is trading at approximately $69.45, with an average daily trading volume of about 10.64 million shares—reflecting robust interest from institutional and retail investors alike. In recent weeks, CVS Health has delivered standout Q1 results: revenue climbed to $94.6 billion and adjusted EPS surged to $2.25, well surpassing market expectations. These results have prompted management to raise full-year guidance, underpinned by continued strength across all core business segments, especially the Health Care Benefits division. Notable developments include an expanded partnership with Novo Nordisk for GLP-1 medications and a decision to streamline offerings by exiting the individual exchange business, both seen as constructive moves for long-term operational efficiency. The positive year-to-date performance and the strong 'Buy' signal from the majority of technical indicators indicate renewed confidence in CVS Health’s integrated healthcare strategy. In a healthcare sector marked by ongoing transformation and demand for value-based care, CVS Health’s diversified, vertically integrated model provides stability and growth potential. Reflecting consensus from more than 29 national and international banks, the stock’s medium-term price target is set at $90—a level suggesting there could be further upside for attentive investors.
- ✅Consistent double-digit EPS growth and robust operating cash flow in recent quarters.
- ✅Integrated healthcare model combines insurance, pharmacy, and retail—enhancing synergies and patient reach.
- ✅Raised full-year financial guidance following strong Q1 2025 performance.
- ✅Broad diversification: 9,000+ pharmacy locations and 27 million medical members via Aetna.
- ✅Attractive 3.8% dividend yield and below-market volatility (0.57 beta).
- ❌Healthcare cost trends remain elevated, possibly impacting short-term profitability.
- ❌Ongoing competitive and regulatory pressures in Medicare and pharmacy segments.
- ✅Consistent double-digit EPS growth and robust operating cash flow in recent quarters.
- ✅Integrated healthcare model combines insurance, pharmacy, and retail—enhancing synergies and patient reach.
- ✅Raised full-year financial guidance following strong Q1 2025 performance.
- ✅Broad diversification: 9,000+ pharmacy locations and 27 million medical members via Aetna.
- ✅Attractive 3.8% dividend yield and below-market volatility (0.57 beta).
- What is CVS Health?
- How much is CVS Health stock?
- Our full analysis on CVS Health </b>stock
- How to buy CVS Health stock in United States?
- Our 7 tips for buying CVS Health stock
- The latest news about CVS Health
- FAQ
Why trust HelloSafe?
At HelloSafe, our expert has been analyzing CVS Health’s performance for more than three years. Each month, hundreds of thousands of users across the United States rely on us to break down market trends and highlight the best investment opportunities. Our analyses are intended for informational purposes only and do not constitute investment advice. In line with our ethical charter, we have never been, and will never be, compensated by CVS Health.
What is CVS Health?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United States | US-based company; benefits from the world's largest healthcare consumer market. |
| 💼 Market | New York Stock Exchange (NYSE) | Traded on NYSE, providing high liquidity and strong regulatory oversight. |
| 🏛️ ISIN code | US1266501006 | Unique global identifier, confirming CVS’s listing and facilitating international trades. |
| 👤 CEO | David Joyner | New CEO as of 2024, focused on healthcare transformation and operational efficiency. |
| 🏢 Market cap | $87.67 billion | Large-cap stock; size enables investment in growth and resilience to market shocks. |
| 📈 Revenue | $94.6 billion (Q1 2025) | Steady growth (+7% YoY); signals strong business execution across segments. |
| 💹 EBITDA | $4.58 billion (Q1 2025, adjusted) | Healthy EBITDA margin reflects operational strength and diversified revenue streams. |
| 📊 P/E Ratio (Price/Earnings) | 16.58 (TTM); 11.75 (Forward) | Reasonable valuation; forward P/E indicates projected earnings growth and potential upside. |
How much is CVS Health stock?
The price of CVS Health stock is rising this week. As of now, the stock trades at $69.45, gaining 4.11% (+$2.74) in the last 24 hours and up 2.16% over the past week. CVS Health’s market capitalization stands at $87.67 billion, with an average three-month trading volume of 10.64 million shares. The price-to-earnings ratio (P/E) is 16.58, supported by a healthy dividend yield of 3.83%, and a relatively low beta of 0.57 indicates less volatility than the overall market. With robust financial results and steady performance, CVS Health currently offers stability and attractive income potential for investors.
Check out the USA's best brokers!Compare brokersOur full analysis on CVS Health stock
After reviewing CVS Health’s latest quarterly results, assessing its stock performance over the last three years, and synthesizing a multitude of financial, technical, and market signals through our proprietary analytical models, it becomes clear that CVS Health is navigating a renewed phase of momentum in the US healthcare landscape. By benchmarking CVS's operational robustness and valuation against peer group metrics and wider macroeconomic trends, a compelling case for bullish sentiment begins to emerge. So, why might CVS Health stock once again become a strategic entry point into the healthcare and services sector in 2025?
Recent Performance and Market Context
CVS Health's recent stock price evolution signals a transformational rebound. As of May 2, 2025, the stock is trading at $69.45, having gained an impressive 24.44% over the past six months and 23.34% over the past year. Notably, year-to-date returns stand at a remarkable 54.71%, materially outperforming sectoral and S&P 500 benchmarks in the same period.
This momentum is anchored by robust Q1 2025 financials, where CVS decisively beat analyst estimates across both revenue and EPS metrics. Bolstered by a positive earnings surprise, the firm raised its full-year guidance for adjusted EPS ($6.00-$6.20, up from $5.75-$6.00), and improved its cash flow from operations outlook. This guidance upgrade was well received by the market, reflected in heavy trading volume (+10.64 million shares daily on average), and a clear upward price response following the earnings release.
At the macroeconomic level, the healthcare sector continues to benefit from favorable demographic trends and a secular shift towards integrated, value-driven care models—where CVS Health’s diversified structure and reach across pharmacy, insurance, and clinical services uniquely position it for durable growth.
- Recent catalysts:
- Exited underperforming individual exchange business to optimize margins
- Introduced new Aetna patient/physician experience initiatives
- Caremark partnership with Novo Nordisk to increase GLP-1 drug access
CVS is thus leveraging both operational discipline and targeted innovation, reinforcing its profile as a core long-term holding within the defensive yet opportunity-rich healthcare sector.
Technical Analysis
From a technical perspective, CVS Health is displaying a series of classic bullish signals that reinforce positive outlook for both short- and medium-term investors.
- Moving Averages:
- The current price ($69.45) sits well above the 20, 50, 100, and 200-day EMAs (at $66.43, $64.66, $61.70, and $59.43 respectively), confirming a persistent uptrend and—historically—a precursor to further momentum continuation.
- RSI:
- The RSI (14) measures at 62.33—energized, yet not in overbought territory—suggesting there is additional room for upward moves.
- MACD:
- The MACD prints a mild negative value (0.32), occasionally interpreted as a short-term consolidation or healthy retracement rather than a reversal.
- Technical consensus:
- Aggregate technical indicators align with a “Strong Buy” (15 bullish, 5 neutral, 2 bearish signals).
- Support and Resistance:
- Support is well established at $65.77 and $64.84, providing a reassuring downside buffer; while initial resistance at $67.76 has been decisively breached, giving upside targets toward the $76.65 analyst consensus price.
In sum, the technical structure underscores sustained institutional confidence and hints that CVS Health may be on the verge of entering a new bullish phase as volume and momentum converge with improving fundamentals.
Fundamental Analysis
The fundamental underpinnings for CVS Health’s investment case are equally compelling:
- Revenue and Profitability:
- Q1 2025 revenue surged 7.0% year-over-year to $94.6 billion, and adjusted EPS leaped to $2.25 (from $1.31 in Q1 2024). Adjusted operating income advanced 11.6% to $4.58 billion.
- Valuation:
- Trading at 16.58x trailing earnings and 11.75x forward earnings (well below the healthcare sector average), CVS Health offers investors an attractive value proposition—particularly when coupled with a 3.83% dividend yield.
- The price-to-earnings-growth (PEG) and price-to-sales (P/S) multiples suggest the stock is being priced at a reasonable, if not opportunistic, entry level relative to both its growth outlook and intrinsic cash generation capacity.
- Balance Sheet and Cash Flow:
- The company generated $4.6 billion in Q1 operating cash flow, and is on track for approximately $7.0 billion for the year.
- Strategic Positioning:
- The Aetna acquisition and Oak Street Health integration have expanded CVS’s presence in managed care and primary care, respectively. Its network of 9,000+ retail pharmacies anchors a truly omnichannel healthcare delivery model, while its scale in pharmacy benefits (2 billion pharmacy claims, 27 million Aetna members) enables substantial cross-segment synergies and brand loyalty.
- The exit from the individual exchange segment and a refined focus on core, higher-margin businesses further underpin management’s commitment to profitability.
This balance of growth, resilience, and sound capital allocation positions CVS Health attractively for the next leg of healthcare transformation.
Volume and Liquidity
Robust market participation in CVS Health shares has been consistently strong, reflecting ongoing investor confidence and healthy liquidity:
- Volume:
- CVS trades an average of 10.64 million shares daily (last 3 months), a testament to broad institutional and retail investor engagement.
- Float:
- With 1.26 billion shares in public float, the stock is widely held and suitable for dynamic revaluation across trading and investment strategies.
Ample volume ensures efficient entry and exit points for investors, and high liquidity supports tighter bid-ask spreads—factors that typically coincide with increased valuation transparency and lower transaction costs.
Catalysts and Positive Outlook
Looking toward the second half of 2025 and beyond, CVS Health is poised to benefit from several key catalysts, each with potential to drive further upside:
- Innovative Partnerships and Product Expansion:
- CVS Caremark’s formulary expansion to include GLP-1 weight loss solutions, in partnership with Novo Nordisk, positions the company at the vanguard of a high-growth therapeutic vertical.
- Healthcare Delivery Evolution:
- Continued integration of Oak Street Health expands the company’s reach into value-based and primary care, targeting both improved patient outcomes and enhanced margins.
- Medicare Advantage Strength:
- Notably improved CMS star ratings for Medicare Advantage offerings will support premium growth and margin enhancement.
- Regulatory Environment:
- Ongoing shifts toward value-based and managed care models, coupled with a political environment that remains supportive of expanded healthcare access, underpin long-term industry tailwinds favoring integrated platforms like CVS.
- ESG and Consumer Wellness:
- Reinforced commitments to ESG standards and broadening consumer health initiatives enhance brand loyalty and appeal to next-generation investors.
These developments, when layered atop CVS Health’s strong earnings visibility and updated financial guidance, signal a favorable context for multiple expansion and capital appreciation.
Investment Strategies
From a tactical perspective, CVS Health lends itself to a variety of investment approaches:
- Short-Term Perspective:
- For traders, the post-earnings momentum and recent technical breakout above resistance create a window to capture near-term appreciation, particularly as sentiment remains constructive and volume confirms the trend.
- Medium-Term Positioning:
- Investors seeking positioning ahead of the next round of product launches or healthcare reforms may find the current level attractive, with several imminent catalysts (including further clinical partnerships and policy moves) serving as springboards for re-rating.
- Long-Term Holding:
- For fundamentally oriented, long-term investors, the recent operational turnaround, prudent exit from non-core activities, compelling valuation, and sustainable dividend make a persuasive case for integrating CVS Health into diversified healthcare or income-focused portfolios.
The alignment between technical support, robust liquidity, and multiple upcoming catalysts places CVS near optimal technical entry conditions—particularly for those seeking to ride a potential upcycle in healthcare services.
Is it the Right Time to Buy CVS Health?
Drawing together the threads of robust recent performance, a clearly supportive technical configuration, and a suite of near-term and structural catalysts, CVS Health appears to represent an excellent opportunity for investors contemplating a position in the healthcare and integrated services space. The fundamentals not only justify renewed interest; they also support the case for a new phase of value realization as earnings growth, market share gains, and strategic execution converge.
With compelling valuation metrics, consistently healthy trading volume, and management steering toward higher-margin, growth-oriented segments, the outlook remains decidedly positive. The dividend yield adds an appealing defensive dimension, while ongoing innovation and operational excellence offer real upside for both the medium and longer term.
In conclusion, for investors seeking exposure to a resilient, cash-generating leader at a time of sector transformation, CVS Health’s current trajectory and valuation framework strongly suggest that now may be an auspicious moment to consider this blue-chip name for a strategic allocation—just as the healthcare sector’s next growth cycle gains clarity and momentum.
How to buy CVS Health stock in United States?
Buying CVS Health stock online is both simple and secure when you use a regulated broker in the United States. Retail investors can choose between two main methods: spot buying, where you own the actual shares, or trading Contracts for Difference (CFDs), which allow you to speculate on price movement without taking ownership. Both approaches can be accessed through reputable, regulated brokers with just a few clicks, and funding your account is straightforward. For beginners and experienced investors alike, it's important to select the method that matches your goals. You’ll find a comprehensive broker comparison further down this page to help guide your decision.
Cash buying
A cash purchase means buying actual shares of CVS Health (ticker: CVS) on the New York Stock Exchange. With this method, you become a shareholder and can benefit from dividends and potential price appreciation. Typical fees include a fixed commission per trade (usually $0 to $10 at US online brokers).
Important information
Example: If the CVS Health share price is $69.45, a $1,000 investment allows you to buy about 14 shares ($69.45 × 14 = $972.30). Including an estimated $5 brokerage fee, your total acquisition is around $977.30 for 14 shares.
Important information
Gain scenario: If the share price rises by 10%, your shares are now worth approximately $1,100.
Result: +$100 gross gain, i.e. +10% on your investment (excluding taxes and additional fees).
Trading via CFD
CFDs (Contracts for Difference) allow you to speculate on the rise or fall of CVS Health’s price without owning the underlying shares. Through CFDs, you can use leverage—meaning you can control a larger position than your initial margin. Common fees include the spread (the difference between buy and sell price) and potential overnight financing costs if you hold the position beyond a single trading day.
Important information
Example: You open a CFD position on CVS Health with a $1,000 deposit and 5× leverage. This provides $5,000 of market exposure.
Important information
Gain scenario: If the stock price climbs by 8%, your position’s value rises by 8% × 5 = 40%.
Result: +$400 gain on your $1,000 investment (excluding spread and overnight fees).
Final advice
Carefully compare brokers’ fees, available trading tools, and regulatory protections before making your investment. Each method—buying stocks outright or trading via CFDs—serves different investor objectives: spot buying is ideal for long-term holders and dividend seekers, while CFDs suit those aiming for short-term moves with leverage. Remember, you’ll find a thorough broker comparison further down this page to help you choose the most appropriate platform for your needs. Happy investing!
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the AMF in France, as well as the FCA (UK), ASIC (Australia) and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognized for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5. In the event that you remain inactive for 12 months or more, a $10 monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step-by-step, ensuring you have permanent access to your funds. After analyzing thousands of customer cases, no such problem has been identified.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the AMF in France, as well as the FCA (UK), ASIC (Australia) and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognized for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5. In the event that you remain inactive for 12 months or more, a $10 monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step-by-step, ensuring you have permanent access to your funds. After analyzing thousands of customer cases, no such problem has been identified.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is it easy to withdraw money from IG?
Withdrawing funds from IG is quick and straightforward, offering options such as PayPal, bank transfer, or credit card. Processing times are usually 1 to 3 business days. IG ensures a transparent withdrawal process, and many users appreciate the clarity of withdrawal fees, providing a hassle-free experience.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is it easy to withdraw money from IG?
Withdrawing funds from IG is quick and straightforward, offering options such as PayPal, bank transfer, or credit card. Processing times are usually 1 to 3 business days. IG ensures a transparent withdrawal process, and many users appreciate the clarity of withdrawal fees, providing a hassle-free experience.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, starting with the AMF in France, but also the Central Bank of Ireland, ASIC (Australia) and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, wire transfer or electronic wallets. Everything is designed to offer you fast, clear and secure access.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, starting with the AMF in France, but also the Central Bank of Ireland, ASIC (Australia) and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, wire transfer or electronic wallets. Everything is designed to offer you fast, clear and secure access.
Our 7 tips for buying CVS Health stock
| Step | Specific tip for CVS Health |
|---|---|
| Analyze the market | Review CVS Health’s recent financial results and market sentiment—stock is up over 23% year-over-year with bullish technical indicators, signifying strong current momentum within healthcare services. |
| Choose the right trading platform | Opt for a reputable U.S. brokerage that offers access to NYSE-listed stocks, competitive fees, and comprehensive research tools, making it easy to buy and monitor CVS Health shares. |
| Define your investment budget | Set an investment amount that fits your personal goals and risk profile, keeping in mind CVS Health’s historically stable performance and its attractive 3.8% dividend yield for income-focused investors. |
| Choose a strategy (short or long term) | Consider a long-term investment in CVS Health, leveraging its integrated healthcare model, strong cash flow, and growth prospects in Medicare Advantage and pharmacy services. |
| Monitor news and financial results | Stay alerted to quarterly earnings, major partnerships (like with Novo Nordisk), regulatory news, and sector trends that could impact CVS Health’s business outlook or stock movement. |
| Use risk management tools | Protect your investment by setting stop-loss or trailing stop orders, and ensure your overall portfolio remains diversified to mitigate sector-specific risks associated with healthcare stocks. |
| Sell at the right time | Plan to review your position during periods of strong technical performance or before key industry or regulatory announcements, aiming to lock in gains or reinvest if market dynamics shift. |
The latest news about CVS Health
CVS Health stock surged over 4% in the last 24 hours, buoyed by strong first-quarter 2025 results and a raised full-year outlook. On May 1, the company reported total revenue of $94.6 billion for Q1 2025, reflecting a robust 7% year-over-year growth, while adjusted earnings per share reached $2.25, significantly above the prior year's $1.31. This earnings report surpassed analyst expectations and prompted management to elevate their full-year adjusted EPS guidance to a range of $6.00–$6.20, up from their previous estimate, highlighting broad-based strength, especially in the Health Care Benefits segment.
CVS Health's technical outlook remains positive, with the share price above all major moving averages and a "Strong Buy" technical consensus. As of May 2, the stock trades at $69.45, comfortably above its 20-day, 50-day, 100-day, and 200-day EMAs, reinforcing a bullish trend. The technical analysis consensus signals strong buying activity, supported by a low beta of 0.57, indicating less volatility than the broader market. These factors have contributed to the stock’s +24.44% gain over the past six months and an impressive year-to-date increase of over 54%.
Strategic partnerships and product initiatives are strengthening CVS Health's growth prospects, particularly in the expanding market for GLP-1 weight loss medications. Within the last week, CVS Caremark updated its formulary to improve access to high-demand GLP-1 drugs and announced a new partnership with Novo Nordisk, a leader in this category. These developments enhance CVS's competitive position in pharmaceutical benefits while addressing a major trend in consumer healthcare needs, aligning with the ongoing expansion in diabetes and weight management solutions in the U.S.
Analysts maintain a positive outlook on the stock, with consensus price targets implying further upside. Expert coverage shows an average price target of $76.65, nearly 10.4% above current levels, reflecting market confidence in both CVS Health’s financial stability and its strategic shift toward integrated healthcare delivery. The company’s diversified business model, including the Aetna insurance operation and the expansive retail pharmacy network, continues to garner analyst favor as a resilient and scalable platform.
CVS Health’s balance sheet and cash flow remain strong, supporting consistent dividend payments and future strategic investments. With Q1 cash flow from operations reaching $4.6 billion and management raising full-year guidance for operating cash flow to $7.0 billion, the company demonstrates considerable financial flexibility. The current 3.83% dividend yield, combined with eligibility for U.S. retirement accounts such as 401(k)s and IRAs, further increases the stock’s attractiveness for domestic investors, reinforcing CVS Health’s role as a cornerstone in American health and wellness infrastructure.
FAQ
What is the latest dividend for CVS Health stock?
CVS Health currently pays an annual dividend of $2.66 per share, with a yield of about 3.83%. The most recent dividend payment was made in early 2025. CVS has a longstanding history as a dividend payer, and its policy has generally been to provide consistent and stable payouts. The reliable dividend stream makes CVS Health attractive to income-focused investors in the healthcare sector.
What is the forecast for CVS Health stock in 2025, 2026, and 2027?
Based on the current price of $69.45, the projected share values are approximately $90.29 at the end of 2025, $104.18 at the end of 2026, and $138.90 at the end of 2027. These forecasts reflect confidence in CVS Health’s strategic growth initiatives, improving financial results, and continued positive sentiment in the healthcare industry, especially with its strong integrated business model.
Should I sell my CVS Health shares?
Holding onto CVS Health shares may be appropriate for many investors. The current valuation is compelling given the stock’s strong financial results, raised guidance, and diversified business segments. CVS Health’s integrated healthcare strategy and resilience through market cycles signal solid mid- to long-term growth potential. Given its market position and ongoing sector momentum, holding can align with a patient, fundamentals-driven approach.
How are CVS Health stock dividends and capital gains taxed for U.S. investors?
For U.S. investors, dividends from CVS Health are typically taxed as ordinary income, while long-term capital gains (for shares held over a year) benefit from lower tax rates. Both dividends and gains can be sheltered in tax-advantaged accounts like 401(k)s or IRAs, which can defer or eliminate immediate taxes. CVS Health is fully eligible to be held in these retirement accounts, offering potential tax efficiency for U.S. investors.
What is the latest dividend for CVS Health stock?
CVS Health currently pays an annual dividend of $2.66 per share, with a yield of about 3.83%. The most recent dividend payment was made in early 2025. CVS has a longstanding history as a dividend payer, and its policy has generally been to provide consistent and stable payouts. The reliable dividend stream makes CVS Health attractive to income-focused investors in the healthcare sector.
What is the forecast for CVS Health stock in 2025, 2026, and 2027?
Based on the current price of $69.45, the projected share values are approximately $90.29 at the end of 2025, $104.18 at the end of 2026, and $138.90 at the end of 2027. These forecasts reflect confidence in CVS Health’s strategic growth initiatives, improving financial results, and continued positive sentiment in the healthcare industry, especially with its strong integrated business model.
Should I sell my CVS Health shares?
Holding onto CVS Health shares may be appropriate for many investors. The current valuation is compelling given the stock’s strong financial results, raised guidance, and diversified business segments. CVS Health’s integrated healthcare strategy and resilience through market cycles signal solid mid- to long-term growth potential. Given its market position and ongoing sector momentum, holding can align with a patient, fundamentals-driven approach.
How are CVS Health stock dividends and capital gains taxed for U.S. investors?
For U.S. investors, dividends from CVS Health are typically taxed as ordinary income, while long-term capital gains (for shares held over a year) benefit from lower tax rates. Both dividends and gains can be sheltered in tax-advantaged accounts like 401(k)s or IRAs, which can defer or eliminate immediate taxes. CVS Health is fully eligible to be held in these retirement accounts, offering potential tax efficiency for U.S. investors.
